PRESS RELEASESCitius Pharmaceuticals To Present At The MoneyShow Accredited Investor Virtual EventBy PR NewswireJul 20, 2020 2:00 PM EDT
PRESS RELEASESCitius Pharmaceuticals Brings On Myron S. Czuczman, M.D. As Chief Medical Officer (CMO) And Executive Vice PresidentBy PR NewswireJul 14, 2020 8:47 AM EDT
PRESS RELEASESCitius Pharmaceuticals Regains Compliance With Nasdaq Listing RequirementsBy PR NewswireJul 13, 2020 8:15 AM EDT
PRESS RELEASESCitius CEO Myron Holubiak To Appear On TD Ameritrade Network's The Watch List With Nicole PetallidesBy PR NewswireJun 29, 2020 9:07 AM EDT
PRESS RELEASESCitius Receives FDA Response On Pre-Investigational New Drug (PIND) Application For Its Induced Mesenchymal Stem Cells (iMSCs) To Treat Acute Respiratory Distress Syndrome (ARDS) In Patients With COVID-19By PR NewswireJun 26, 2020 9:00 AM EDT
PRESS RELEASESCitius Pharmaceuticals To Deliver Virtual Presentation At The Life Sciences Investor ForumBy PR NewswireJun 22, 2020 1:17 PM EDT
PRESS RELEASESCitius Receives Positive FDA Feedback On Its Submitted Plan To Study Catheter Compatibility For Mino-Lok® TherapyBy PR NewswireJun 2, 2020 9:30 AM EDT
PRESS RELEASESCitius Announces Expanded Access Program For Investigational Phase 3 Mino-Lok®By PR NewswireMay 26, 2020 8:15 AM EDT
PRESS RELEASESCitius Announces Closing Of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesBy PR NewswireMay 18, 2020 2:30 PM EDT
PRESS RELEASESCitius Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesBy PR NewswireMay 14, 2020 9:00 AM EDT
PRESS RELEASESCitius Announces Data On NoveCite Mesenchymal Stem Cells (NC-MSCs) To Be Presented At The American Society Of Gene And Cell Therapy (ASGCT) Annual MeetingBy PR NewswireMay 13, 2020 8:15 AM EDT
PRESS RELEASESCitius Pharmaceuticals Issues May 2020 Shareholder LetterBy PR NewswireMay 12, 2020 8:00 AM EDT
PRESS RELEASESCitius Announces Pre-IND Submission To FDA Under The Coronavirus Treatment Acceleration Program For A Novel Stem Cell Therapy For Acute Respiratory Distress Syndrome (ARDS) In COVID-19By PR NewswireApr 27, 2020 9:30 AM EDT
PRESS RELEASESCitius Signs Exclusive Option With Novellus To License Novel Stem-Cell Therapy For Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19By PR NewswireApr 1, 2020 8:07 AM EDT
PRESS RELEASESCitius Pharmaceuticals Announces Publication In Antimicrobial Agents And Chemotherapy Journal Of Positive Preclinical Results For Mino-Lok® In Rapidly Eradicating Candida AurisBy PR NewswireMar 26, 2020 9:06 AM EDT
PRESS RELEASESCitius Pharmaceuticals To Deliver Virtual Presentation At The Spring Investor SummitBy PR NewswireMar 18, 2020 9:46 AM EDT
PRESS RELEASESCitius Pharmaceuticals To Present At The 2020 LD Micro Virtual ConferenceBy PR NewswireFeb 26, 2020 8:00 AM EST
PRESS RELEASESCitius Pharmaceuticals Cites Independent Estimates Of Total Available World Market For Mino-Lok®By PR NewswireFeb 25, 2020 8:00 AM EST
PRESS RELEASESCitius Pharmaceuticals To Present At Noble Capital Markets' 16th Annual Investor ConferenceBy PR NewswireFeb 10, 2020 8:28 AM EST
PRESS RELEASESCitius Pharmaceuticals Regains Compliance With Nasdaq Listing RequirementsBy PR NewswireFeb 3, 2020 8:00 AM EST
